Search results for "reimbursement"

showing 10 items of 48 documents

Innovation in cardiovascular disease in Europe with focus on arrhythmias: current status, opportunities, roadblocks, and the role of multiple stakeho…

2018

The European Heart Rhythm Association (EHRA) held an Innovation Forum in February 2016, to consider issues around innovation. The objective of the forum was to extend the innovation debate outside of the narrow world of arrhythmia specialists and cardiology in general, and seek input from all stakeholders including regulators, strategists, technologists, industry, academia, health providers, medical societies, payers, and patients. Innovation is indispensable for a continuing improvement in health care, preferably at higher efficacy and lower costs. It requires people who have been trained in a good scientific environment, high-quality research for achieving ground breaking inventions and t…

0301 basic medicineBig Datamedia_common.quotation_subjectBig dataBasic scienceContext (language use)Disease030204 cardiovascular system & hematologyArrhythmias03 medical and health sciences0302 clinical medicinePhysiology (medical)Health careDevicesGeneticsMedicineInnovationReimbursementPatentsmedia_commonbusiness.industryComputer modelsCertaintyPublic relationsPersonalized medicineReimbursementElectrophysiologyClinical trial030104 developmental biologyCardiology and Cardiovascular MedicinebusinessRisk assessmentHealthcare providers
researchProduct

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO…

2017

The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account t…

0301 basic medicinemedicine.medical_specialtyChinaColorectal cancerDrug availabilityEthnic groupTaiwanConsensuSystemic therapyScientific evidence03 medical and health sciences0302 clinical medicineAsian PeopleRepublic of KoreaAsian countrymedicineHumansNeoplasm MetastasisReimbursementClinical OncologyClinical practice guidelinePan-Asianbusiness.industryMalaysiaHematologymedicine.diseaseColorectal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicinebusinessColorectal NeoplasmsAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region

2019

Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low …

0301 basic medicinemedicine.medical_specialtyConsensusEndocrinology Diabetes and MetabolismOsteoporosis030209 endocrinology & metabolismBone resorption makerAsia pacific regionCollagen Type IBone remodeling03 medical and health sciences0302 clinical medicineN-terminal telopeptideBone DensityOsteoporosis treatmentHealth caremedicineHumansRadiology Nuclear Medicine and imagingOrthopedics and Sports MedicineIntensive care medicineReimbursementAnabolicsBone mineralddc:616Hip Fracturesbusiness.industryAnti-resorptivesmedicine.diseasePeptide FragmentsBone formation makerOsteoporosisBone Remodeling030101 anatomy & morphologybusinessBiomarkersProcollagen
researchProduct

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: …

2020

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treat…

0301 basic medicinemedicine.medical_specialtyESMO guidelinesDrug availability03 medical and health sciences0302 clinical medicineAdvanced diseaseAsian countryconsensuMedicineHCCReimbursementESMO guidelinePan-Asianbusiness.industryCancer conferenceRelapsed Hepatocellular CarcinomaHematologyhepatocellular carcinomaClinical Practice030104 developmental biologyOncologyconsensus030220 oncology & carcinogenesisFamily medicinebusiness
researchProduct

Applying RUG-III for reimbursement of nursing facility care

2006

The Resource Utilization Groups (RUG-III) case-mix classification is becoming an internationally accepted methodology for determining payment for nursing facility and care. In this paper we discuss the key concepts of case-mix reimbursement and several different payment approaches based on RUG-III. In discussing the empirical evidence of case-mix reimbursement, we draw especially on the US experience. Clearly, the success of case-mix reimbursement depends not only on the payment design, but also on the ability to foresee market conditions and the regulatory environment in which the payment system is being implemented. Moreover, we demonstrate the need to develop a case-mix based reimburseme…

Actuarial scienceLeadership and Managementbusiness.industrymedia_common.quotation_subjectPublic sectorPayment systemHealth InformaticsPaymentLong-term careNursing careIncentiveCase mix indexBusinessReimbursementmedia_commonInternational Journal of Healthcare Technology and Management
researchProduct

Trends in individual reimbursement of orphan drugs in Latvia in 2008–2011

2014

Orphan drugs (ODs) are medicinal products intended for diagnosis, prevention or treatment of life-threatening or very serious diseases affecting less than 5 in 10 000 people in the European Union (EU). These drugs are called “orphans” because the pharmaceutical industry has little interest, under normal market conditions, in developing and marketing products intended for only a small number of patients suffering from very rare conditions. Because of the small market, ODs are often very expensive. Whereas decisions surrounding orphan designation and marketing authorization of ODs are taken at the EU level, decisions governing pricing and reimbursement of ODs are a member state responsibility…

Actuarial sciencebusiness.industryDrug reimbursementMarketing authorizationlcsh:Social Scienceslcsh:HOrphan drugMember stateMedicinemedia_common.cataloged_instancePer patient per yearEuropean unionbusinessReimbursementPharmaceutical industrymedia_commonSHS Web of Conferences
researchProduct

Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women…

2016

PURPOSE: The 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/predictive information in oestrogen receptor positive (ER+) early breast cancer, but access/reimbursement has been limited in most European countries in the absence of prospective outcome data. Recently, two large prospective studies and a real-life 5-year outcome study have been reported. We performed a pooled analysis of prospective European impact studies to generate robust data on impact of use in different clinical subgroups. METHODS: The analysis included four studies (French, German, Spanish, and British) in ER+ human epidermal growth factor receptor 2-negative breast cancer patients (n = 527). Node-positiv…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentClinical Decision-MakingBreast NeoplasmsMama -- Càncer -- TractamentRisk AssessmentSeverity of Illness Index03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerInternal medicineQuimioteràpiaHumansMedicineProspective StudiesOestrogen receptorPrecision MedicineStage (cooking)Prospective cohort studyReimbursementAgedAged 80 and overGynecologyChemotherapyIndividualised medicinemedicine.diagnostic_testbusiness.industryGene Expression ProfilingMiddle Agedmedicine.diseaseTumor BurdenAdjuvant chemotherapyEurope030104 developmental biologyReceptors EstrogenOncology030220 oncology & carcinogenesisHormonal therapyFemaleNeoplasm Recurrence LocalbusinessOncotype DXClinical decision makingEuropean Journal of Cancer
researchProduct

The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy

2019

Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, …

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyHBsAgCirrhosisHBV reactivationHbv markersHbv reactivationPrevalenceHbv vaccinationHepacivirusChronic liver diseaseAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicinePrevalencemedicineHumansHepatitis B AntibodiesReimbursementAgedHepatitis B Surface AntigensHepatologyCoinfectionbusiness.industryGastroenterologyHCV therapyvirus diseasesHepatitis C ChronicMiddle AgedHepatitis Bmedicine.diseaseChronic HCV infection; HBV reactivation; HBV/HCV coinfection; HCV therapydigestive system diseasesHBV/HCV coinfectionItalyChronic HCV infection030220 oncology & carcinogenesisDNA ViralFemaleVirus Activation030211 gastroenterology & hepatologybusiness
researchProduct

Telemedicine and COVID-19 pandemic: The perfect storm to mark a change in diabetes care. Results from a world-wide cross-sectional web-based survey

2021

Abstract Background Telemedicine for routine care of people with diabetes (PwD) during the COVID‐19 pandemic rapidly increased in many countries, helping to address the several barriers usually seen. Objective This study aimed to describe healthcare professionals' (HCPs) experience on telemedicine use in diabetes care and investigate the changes and challenges associated with its implementation. Methods A cross‐sectional electronic survey was distributed through the global network of JENIOUS members of ISPAD. Respondents' professional and practice profiles, clinic sizes, their country of practice, and data regarding local telemedicine practices during COVID‐19 pandemic were investigated. Re…

AdultMaleTelemedicineClinical Care and TechnologyInternationalityCoronavirus disease 2019 (COVID-19)pediatricstelehealthtype 1 diabetesHealth PersonnelEndocrinology Diabetes and MetabolismTelehealthCOVID‐19Surveys and QuestionnairesGlobal networkPandemicDiabetes MellitusInternal MedicinemedicineHumansData Protection Act 1998PandemicsReimbursementAgedAged 80 and overInternetbusiness.industryCOVID-19Middle Agedmedicine.diseaseWorld wideCross-Sectional StudiesPrivacyPediatrics Perinatology and Child HealthFemalevirtualMedical emergencytelemedicinebusinessPediatric Diabetes
researchProduct

European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring

2014

Given the increasing use of ambulatory blood pressure monitoring (ABPM) in both clinical practice and hypertension research, a group of scientists, participating in the European Society of Hypertension Working Group on blood pressure monitoring and cardiovascular variability, in year 2013 published a comprehensive position paper dealing with all aspects of the technique, based on the available scientific evidence for ABPM. The present work represents an updated schematic summary of the most important aspects related to the use of ABPM in daily practice, and is aimed at providing recommendations for proper use of this technique in a clinical setting by both specialists and practicing physici…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureAdolescentPhysiologyMEDLINEPharmacyWhite coat hypertensionPractice PatternsBlood Pressure MonitoringMasked HypertensionAtrial FibrillationAmbulatoryInternal MedicinemedicineHumansambulatory blood pressure monitoring arterial hypertension clinic blood pressure measurement clinical indications guidelines home blood pressure measurement practice recommendationsObesityPractice Patterns Physicians'ChildIntensive care medicineReimbursementPhysicians'business.industryMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring Ambulatorymedicine.disease3. Good healthMasked HypertensionBlood pressureHypertensionPosition paperFemaleCardiology and Cardiovascular MedicinebusinessSoftwareWhite Coat HypertensionJournal of Hypertension
researchProduct